New hope for nigerians with colorectal cancer: immunotherapy trial launches
NCT ID NCT06529523
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times
Summary
This study tests a drug called tislelizumab in 40 people in Nigeria who have a specific type of colorectal cancer (mismatch repair deficient) and have not had treatment before. The goal is to see if the drug can shrink tumors and is safe. It is a phase 2 trial, meaning it is still being tested for effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Lagos University Teaching Hospital
NOT_YET_RECRUITINGIdi-Araba, Lagos, Nigeria
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Obafemi Awolowo University Teaching Hospital
NOT_YET_RECRUITINGIle-Ife, Nigeria
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.